Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 49 min ago
Peer-reviewedCC BY-NC-NDJournal of The American Academy of Dermatology

Striking leflunomide efficacy against refractory cutaneous sarcoidosis

  • Gérôme Bohelay
  • Jean-David Bouaziz
  • Hilario Nunes
  • Michel Rybojad
  • Martine Bagot
  • Antoine Petit
  • Liliane Laroche
Open at sourcePDFDOICite

Abstract

To the Editor: Sarcoidosis, a multisystemic granulomatous disease of unknown etiology, involves the skin in about 25% of cases.1 We describe leflunomide efficacy in 2 patients whose cutaneous sarcoidoses were refractory to conventional therapies.

Related

  1. PO048 | EFFICACY OF RITUXIMAB TREATMENT IN A CASE OF A RELAPSED AND REFRACTORY ACQUIRED VON WILLEBRAND DISEASE SECONDARY TO PRIMARY CUTANEOUS MARGINAL ZONE B-CELL LYMPHOMA
    Laura Gurgoglione
    Bleeding, Thrombosis and Vascular BiologyPeer-reviewedCC BY-NCFull textCardiovascular medicineDOAJ
  2. Upadacitinib for refractory cutaneous disease in a patient with tif1γ-positive dermatomyositis
    Yusuf Demir, Hande Ogun, Bercemhan Sulu +2
    Anais Brasileiros de DermatologiaPeer-reviewedCC BYFull textEpidemiology & public healthDOAJ
  3. Efficacy and safety of ultrasound-guided microwave “Near-Total Ablation” for refractory hyperthyroidism: a retrospective study
    Fenglin Wu, Shicong Song, Junyu Xue +4
    Frontiers in endocrinologyPeer-reviewedCC BYFull textEndocrinology & metabolismEurope PMC
  4. Efficacy and safety of P2X3 receptor antagonists in refractory or unexplained chronic cough: an updated systematic review and meta-analysis
    Yu-Tong An, Shu-Ze Tang, Yi Luo +2
    Frontiers in pharmacologyPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
  5. 1187 Safety and efficacy of cesalatamig, a novel PD-1/VEGF bispecific antibody, as monotherapy in PD-(L)1–resistant/refractory NSCLC: Results from global, multicenter, open-label phase 1/2 studies
    Yang Liu, Yu Liu, Fawzi Abu Rous +31
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ

Cite

BibTeXRIS
BibTeX
@article{bohelay2026striking,
  title = {{Striking leflunomide efficacy against refractory cutaneous sarcoidosis}},
  author = {Gérôme Bohelay and Jean-David Bouaziz and Hilario Nunes and Michel Rybojad and Martine Bagot and Antoine Petit and Liliane Laroche},
  journal = {Journal of The American Academy of Dermatology},
  year = {2026},
  month = oct,
  doi = {10.1016/j.jaad.2013.10.048},
  url = {https://hal.science/hal-05790961v1},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Striking leflunomide efficacy against refractory cutaneous sarcoidosis
AU  - Gérôme Bohelay
AU  - Jean-David Bouaziz
AU  - Hilario Nunes
AU  - Michel Rybojad
AU  - Martine Bagot
AU  - Antoine Petit
AU  - Liliane Laroche
PY  - 2026
DA  - 2026/10/10
JO  - Journal of The American Academy of Dermatology
DO  - 10.1016/j.jaad.2013.10.048
UR  - https://hal.science/hal-05790961v1
AB  - To the Editor: Sarcoidosis, a multisystemic granulomatous disease of unknown etiology, involves the skin in about 25% of cases.1 We describe leflunomide efficacy in 2 patients whose cutaneous sarcoidoses were refractory to conventional therapies.
SN  - 0190-9622
SN  - 1097-6787
ER  -